Fungal Microbiome (mycobiome) and Fungi with Probiotic Properties as a Diagnostic Marker, Therapeutic Target and a Tool for Treatment of Intestinal Disorders, Obesity, Metabolic Diseases, Cancer and Neurological Disorders
Novel Fungal Mycobiome as a Diagnostic Marker and Therapeutic Target
Inventors: David Underhill, PhD and Lliyan Lliev
Intellectual Property Status: PCT/US2013/038466 filed on 04/26/2013
This invention discovers that 1) members of the fungal mycobiome can be utilized as probiotics and nutritional ingredients to influence health and disease, 2) relative changes in the fungal mycobiome can be used as a prognostic marker of disease development and severity, and 3) modulation of this community by using existing anti-fungal drugs or certain bacterial species can be applied as a therapeutic tool in different pathologic conditions.
Dr. Underhill and colleague at the Cedars-Sinai Medical Center have discovered that gut fungal microbial community “gut mycobiome” interacts with the gut bacterial community and the host immune system to influence disease and health. It is well known that gut resident microbes are essential for host physiology and provide many benefits to the host including proper development of the immune system and protection from pathogens. Vast majority of prior studies have focused on gut bacteria, and these studies have definitively established roles for a variety of specific gut bacteria in balancing host immunity, protecting from diseases and maintaining health. For the first time our inventors show that certain members of the gut mycobiome can also impart useful benefits similar to bacterial probiotics, and can be utilized as probiotics and nutritional ingredients to confer health benefits to the host.
The present invention provides a method of diagnosing inflammatory bowel disease based on the composition of fungal strains present in the gut of a patient, and treatment by administering a probiotic biotherapy. The method can also diagnose a severe form of ulcerative colitis by detecting a gene expression deficiency in the gut micobiome. Modulation of gut mycobiome by using existing therapeutic anti-fungal drugs in some pathologic conditions is suggested to favorably improve the health of the patient. This method avoids surgical risks, reduces nutritional impact, and is reversible in the case that side effects are encountered.
- Novel probiotics ingredient
- Prognostic and therapeutic benefits with gut disease diagnosis and treatment
Publication Iliev et al (2012). Interactions between Commensal Fungi and the C-Type Lectin Receptor Dectin-1 Influence Colitis. Science, 336 (6086): 1314-1317
For more information, please contact Cedars-Sinai Office of Technology Transfer: